close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

23.96 -0.50 (-2.02%)
Streaming Delayed Price Updated: 3:37 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
30 31 Next >
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Things aren't as bad as they might seem. 
Via The Motley Fool
6 Great Stocks to Buy in 2023 and Hold Forever
I own all six great businesses and don't plan to sell a single share. 
Via The Motley Fool
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
Catalyst is adding to its portfolio with a $160 million deal. 
Via Investor's Business Daily
Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025
A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals. 
Via The Motley Fool
Dow, Nasdaq Boasting Triple-Digit Midday Lead
Investors seem intent on leaving last week's losses behind, as earnings season heats up. 
Via Talk Markets
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product
 
Via Benzinga
Analyst Ratings for Teva Pharmaceutical Indus
 
Via Benzinga
3 Dirt Cheap Stocks to Buy in January
Bargains can easily be found as the new year gets underway. 
Via The Motley Fool
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
 
Via Benzinga
Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday
JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market... 
Via Benzinga
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Organon Stock Scores Market Leadership With Jump To 83 RS Rating
Organon sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today
The stock has gone on a wild ride over the past few years. 
Via The Motley Fool
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Most Active Equity Options For Midday - Wednesday, Jan. 11
Here are the most active equity options for midday. 
Via Talk Markets
NVAX Stock Alert: What to Know as Novavax Names New CEO
Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries. 
Via InvestorPlace
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
From Teva Pharmaceutical Industries Limited
Via Business Wire
4 Stocks That Actually Increased in 2022 -- And They're Still Worth Buying Now
These all handily outperformed the market last year and could do the same in 2023. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2023 Kick-Off With Apple Losing $2T With Big Option Trades On GLD And XLE
While the tenor was more bearish, the late-day rally found the market close to where it finished 2022. 
Via Talk Markets
Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 "Safe" Stocks That Are Anything But
Sometimes, business models that sound safe still fail to deliver for shareholders. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
My Top 5 Portfolio Holdings for 2023
This mix of growth and value stocks can outperform in a challenging environment. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today